Combined local fibrinolysis and intravenous abciximab in acute stroke treatment. FAST-study, background and study design;Kombination einer intraarteriellen rt-PA- plus intravenöser abciximab-therapie bei akuten thromboembolischen Verschlüssen der Arteria cerebri media: Eine dosisfindungsstudie

Klinische Neuroradiologie

Volumn 12, Issue 3, 2002, Pages 127-135

  Eckert, Bernd ^a   Kucinski, Thomas ^a   Wittkugel, Oliver ^a   Roether, Joachim ^a   Solymosi, László ^b   Gödicke, Jochen ^c   Zeumer, Hermann ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Abciximab; Fibrinolysis; Ischemic stroke; Middle cerebral artery; Monoclonal antibodies; Stroke trial; Thrombolytic therapy

Indexed keywords

ABCIXIMAB; ALTEPLASE; PLASMINOGEN; UROKINASE;

ADULT; AGED; ALGORITHM; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; RECANALIZATION; STROKE; TREATMENT OUTCOME;

EID: 0036743196     PISSN: 09397116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00062-002-3334-6     Document Type: Article

References (35)

1. Abumiya T, Fitridge R, Mazur C, Copeland BR, Koziol JA, Tschopp JF, Pierschbacher MD, del Zoppo GJ. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 2000;31:1402-9.
2. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999;99:2720-32.
3. Bartorelli AL, Trabattoni D, Galli S, Grancini L, Cozzi S, Ravagnani P. Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv 1999;48:211-3.
4. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M. Measurements of acute cerebral infarction: a cinical examination scale. Stroke 1989;20:864-70.
5. Cecena FE, Hoelzinger DH, Miller JA, et al. The platelet IIb/IIIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions. J Interven Cardiol 1999;12:355-62.
6. Choudri TF, Hoh BL, Zerwes H-G, et al. Reduced Microvascular Thrombosis and Improved Outcome in Acute Murine Stroke by Inhibiting GP IIb/IIIa Receptor-mediated Platelet Aggregation. J Clin Invest 1998;102:1301-10.
7. Eckert B, Koch C, Thomalla G, Roether J, Zeumer H. Acute basilar artery occlusion treated with combined IV Abciximab and IA t-PA: Report of 3 cases. Stroke 2002;33:1424-7.
8. Eckert B, Kucinski T, Pfeiffer G, Groden C, Zeumer H. Endovascular Therapy of Acute Vertebrobasilar Occlusion: Early treatment onset as the most important factor. Cerebrovasc Dis 2002;14:42-50.
9. Ellis SG, Tcheng JE, Navetta FI, Muller DW, Weisman HF, Smith C, Anderson KM, Califf RM, Topol EJ. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis 1993;4:167-75.
10. Foster RH, Wiseman LR. Abciximab. An updated review of its use in ischaemic heart disease. Drugs 1998;56:629-65.
11. Freitag HJ, Becker V, Thie A, Tilsne RV, Philapitisch A, Schwarz H, Webhof U, Müller A, Zeumer H. Plasminogen plus rt-PA improves intraarterial thrombolytic therapy in acute ischemic stroke. In: Yamaguchi M, Minematsu, del Zoppo, ed. Thrombolytic therapy in acute ischemic stroke III. Berlin-New York: Springer, 1995.
12. Freitag HJ, Becker VU, Thie A, Tilsner V, Philapitsch A, Schwarz HP, Webhof U, Muller A, Zeumer H. Lys-plasminogen as an adjunct to local intra-arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings. Neuroradiology 1996;38:181-5.
13. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-11.
14. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E, Group. ftTS. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879-88.
15. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 1997;95:1755-9.
16. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). Jama 1995;274:1017-25.
17. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators [see comments]. Lancet 1998;352:1245-51.
18. Hamm C, Heeschen C, Goldmann B et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1757-62.
19. Investigatiors. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
20. Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001;357:1905-14.
21. Investigators. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
22. Investigators. Abciximab in Acute Ischemic Stroke. A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study. Stroke 2000;31:601-9.
23. Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study [published erratum appears in Lancet 1997;350(9079):744]. Lancet 1997;349:1429-35.
24. Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
25. Investigators. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985;312:932-6.
26. Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
27. Lee KY, Heo JH, Lee SI, Yoon PH. Rescue treatment with abciximab in acute ischemic stroke. Neurology 2001;56:1585-7.
28. Lempert TE, Malek AM, Halbach VV, Phatouros CC, Dowd CF, Higashida RT. Rescue treatment of acute parent vessel thrombosis with glycoprotein IIb/IIIa inhibitor during GDC coil embolization [letter]. Stroke 1999;30:693-5.
29. Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997;30:1729-34.
30. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-701.
31. Oureshi AI, Suri MF, Khan J, Fessler RD, Guterman LR, Hopkins LN. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience. Neurosurgery 2000;46:1316-24; discussion 1324-5.
32. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64.
33. Tong FC, Cloft HJ, Joseph GJ, Samuels OB, Dion JE. Abciximab rescue in acute carotid stent thrombosis. AJNR Am J Neuroradiol 2000;21:1750-2.
34. Wallace RC, Furlan AJ, Moliterno DJ, Stevens GH, Masaryk TJ, Perl J, 2nd. Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor. AJNR Am J Neuroradiol 1997;18:1257-60.
35. Zeumer H, Freitag HJ, Zanella F, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology 1993;35:159-62.